PE20040288A1 - Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico - Google Patents

Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Info

Publication number
PE20040288A1
PE20040288A1 PE2003000221A PE2003000221A PE20040288A1 PE 20040288 A1 PE20040288 A1 PE 20040288A1 PE 2003000221 A PE2003000221 A PE 2003000221A PE 2003000221 A PE2003000221 A PE 2003000221A PE 20040288 A1 PE20040288 A1 PE 20040288A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
fluoroanilino
pharmaceutical compositions
phenylacetic acid
Prior art date
Application number
PE2003000221A
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Jurij Holinej
Yatindra Joshi
Maha Y Khaled
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040288A1 publication Critical patent/PE20040288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA PARA TRATAR UN DESORDEN O CONDICION DEPENDIENTE DE LA CICLOOXIGENASA-2, COMPRENDIDA ENTRE 200mg Y 400mg DE ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO O LUMIRACOXIB, SIENDO EL NIVEL DE HUMEDAD RESIDUAL (LOD) DE ESTA COMPOSICION ENTRE 1.5% Y 5% APROXIMADAMENTE, PUDIENDO SER TABLETAS O TABLETAS RECUBIERTAS CON PELICULAS.TAMBIEN SE REFIERE A GRANULACIONES SECAS UTILES PARA FABRICAR COMPOSICIONES CONSTITUIDO POR LUMIRACOXIB, CELULOSA MICROCRISTALINA, LACTOSA Y CROSCAMELOSA DE SODIO, DONDE EL NIVEL DE HUMEDAD RESIDUAL ES ENTRE 2.5% A 4.5% APROXIMADAMENTE U OTRAS GRANULACIONES SECAS QUE COMPRENDE LUMIRACOXIB, CROSCAMELOSA DE SODIO Y POVIDONA CON UN LOD DE 1.5% A 4% APROXIMADAMENTE.TAMBIEN SE REFIERE A UN METODO PARA ESTABILIZAR EL COMPUESTO EN UNA COMPOSICION FARMACEUTICA
PE2003000221A 2002-03-07 2003-03-06 Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico PE20040288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36235102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PE20040288A1 true PE20040288A1 (es) 2004-06-24

Family

ID=27789154

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000221A PE20040288A1 (es) 2002-03-07 2003-03-06 Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico

Country Status (20)

Country Link
US (4) US20050123604A1 (es)
EP (1) EP1492520A1 (es)
JP (1) JP2005519097A (es)
KR (1) KR20040089654A (es)
CN (1) CN1330300C (es)
AR (1) AR038747A1 (es)
AU (1) AU2003227039B2 (es)
BR (1) BR0308156A (es)
CA (1) CA2476744A1 (es)
CO (1) CO5650241A2 (es)
EC (1) ECSP045244A (es)
MX (1) MXPA04008665A (es)
NO (1) NO20044164L (es)
NZ (1) NZ534587A (es)
PE (1) PE20040288A1 (es)
PL (1) PL370907A1 (es)
RU (1) RU2318497C2 (es)
TW (1) TW200305443A (es)
WO (1) WO2003074041A1 (es)
ZA (1) ZA200406226B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346525A1 (de) * 1983-12-22 1985-07-04 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
AU660824B2 (en) * 1992-06-12 1995-07-06 Teijin Limited Pharmaceutical preparation for intra-airway administration
CA2163111C (en) * 1993-06-08 2010-10-26 Peter Heinrich Stahl Process for the preparation of an oral solid dosage form containing diclofenac
JPH11512754A (ja) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド シクロオキシゲナーゼ―２媒介疾患の一日一回治療用組成物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE19931708A1 (de) * 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
AU2003227039B2 (en) 2007-04-19
WO2003074041A1 (en) 2003-09-12
RU2004129770A (ru) 2005-05-10
CA2476744A1 (en) 2003-09-12
MXPA04008665A (es) 2004-12-06
RU2318497C2 (ru) 2008-03-10
US20090149543A1 (en) 2009-06-11
PL370907A1 (en) 2005-05-30
ECSP045244A (es) 2004-09-28
NZ534587A (en) 2007-08-31
EP1492520A1 (en) 2005-01-05
KR20040089654A (ko) 2004-10-21
JP2005519097A (ja) 2005-06-30
AR038747A1 (es) 2005-01-26
BR0308156A (pt) 2005-01-04
CO5650241A2 (es) 2006-06-30
US20050123604A1 (en) 2005-06-09
US20070087051A1 (en) 2007-04-19
ZA200406226B (en) 2005-06-23
TW200305443A (en) 2003-11-01
CN1638752A (zh) 2005-07-13
AU2003227039B9 (en) 2003-09-16
CN1330300C (zh) 2007-08-08
US20030171437A1 (en) 2003-09-11
NO20044164L (no) 2004-09-30
AU2003227039A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
AR029819A1 (es) Parche con pantalla ultravioleta
AR014778A1 (es) SISTEMA TERAPÉUTICO PERCUTÁNEO, PROCEDIMIENTO PARA SU FABRICACIoN.
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DK50487A (da) Phenoliske thioethere og farmaceutisk acceptable salte deraf samt dens anvendelse som lipoxygenaseinhibitorer
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
BR9911579A (pt) Uso de um composto antimicrobiano para desinfecção
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
WO2008093686A1 (ja) 非ステロイド系抗炎症薬と有機アミン化合物との塩とその用途
CL2007002407A1 (es) Compuestos derivados de aril-sulfonamidas y sus sales, con accion analgesica; medicamento que los contiene; su procedimiento de preparacion; y uso de los compuestos para el tratamiento agudo y profilactico de dolores, migraña, enfermedades de las vias respiratorias, inflamacion gastrica u otras enfermedades inflamatorias, entre otras.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
HUP0102255A2 (hu) VLA-4 inhibitor hatású oMePUPA-V, ezt tartalmazó gyógyszerkészítmény és alkalmazása
BRPI0617180B8 (pt) processo para produção de uma mistura diretamente comprimível, formulação de ibuprofeno produzida pelo processo, e, forma de dosagem farmacêutica
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
BR9910445A (pt) Preparação farmacêutica
PE20040288A1 (es) Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
HUP0301128A2 (hu) 5-Metil-2-(2'-kloro-6'-fluoranilino)-fenilecetsavat tartalmazó gyógyszerkészítmények ciklooxigenáz-2-vel kapcsolatos betegségek kezelésére és alkalmazásuk
CL2004000512A1 (es) Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes
BR9707931A (pt) Derivados sulfurados comportando um ligação amida seu processo de prepara sua aplicação a título de medicamentos e as composições farmacêuticas que os contêm
AR042712A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans
BRPI0418726A (pt) naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo

Legal Events

Date Code Title Description
FC Refusal